Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), has disclosed plans to enter into an exclusive licensing agreement with its parent company. Under this agreement, Guojian will grant 3SBio the Greater China rights to seven pipeline candidates, including 706, 709, HBT-2002, QY-F10, QY-F11, QY-F07, and QY-F02. In return, 3SBio will make an upfront payment of RMB 236.14 million (USD 32.6 million), with additional milestone payments and royalties on future sales to be disclosed later.
706 is a bispecific antibody (BsAb) that targets PD-1 and PD-L1. It has received Investigational New Drug (IND) approval in both China and the US and is currently undergoing a Phase I study.
The drug candidate 709 is another bispecific antibody that targets PD-1 and LAG3, currently at the IND filing stage.
HBT-2002 is a tri-specific antibody in the pre-clinical stage designed to effectively avoid the mismatch of three antibodies and to activate T cells to recognize and continuously kill tumor cells.
QY-F02 is an immunotoxin, a targeted HER2 nanoantibody immunotoxin developed by the company. It has undergone optimization to remove virtually all T and B cell binding sites. Preclinical studies have shown that QY-F02 has superior in vitro and in vivo efficacy compared to conventional antibody-drug conjugates (ADCs), and the project is currently in preclinical development.
QY-F07 is a bispecific fusion protein based on T-cell activation negative regulatory proteins TIGIT and CTLA4. The project has obtained a more active TIGIT mutant through engineering modification and is in the preclinical stage.
QY-F10 is a recombinant human hyaluronidase PH20 (rhuPH20) developed by the company. It is intended to be combined with biological products to form a fixed-dose compound that assists in the penetration and absorption of subcutaneous injection drugs. The project is in the preclinical stage.
Lastly, QY-F11 is a fusion protein specifically targeting C3b, constructed using the natural regulatory proteins CRIg and FH of C3b. The engineering modification of CRIg significantly improves its biological function, making it a promising candidate for the treatment of complement hyperactivation diseases. The project is in the preclinical stage.- Flcube.com
